About Putative GTP-binding protein 6
Putative GTP-binding protein 6 (GTPBP6) is a protein
from Homo sapiens identified by UniProt accession
O43824, 516 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Putative GTP-binding protein 6 |
| UniProt accession | O43824 |
| Gene | GTPBP6 |
| Organism | Homo sapiens |
| Length | 516 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (14)
Diseases linked to this target (Open Targets).
- influenza · score 0.01
- infection · score 0.01
- infect · score 0.01
- Klinefelter's syndrome · score 0.01
- schizophrenia · score 0.01
- Granulocytopenia · score 0.00
- Leri-Weill dyschondrosteosis · score 0.00
- language impairment · score 0.00
- Lyme disease · score 0.00
- diphtheria · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43824-F1 | alphafold | PREDICTED | 77.46 | — |
Amino-acid sequence (516 residues)
MWALRAAVRP GLRLSRVGRG RSAPRAAAPS CPARALAAVG RRSPGNLEGP WGGGRGLRAD GGRSRTGDDE EEPEDADENA EEELLRGEPL LPAGTQRVCL VHPDVKWGPG KSQMTRAEWQ VAEATALVHT LDGWSVVQTM VVSTKTPDRK LIFGKGNFEH LTEKIRGSPD ITCVFLNVER MAAPTKKELE AAWGVEVFDR FTVVLHIFRC NARTKEARLQ VALAEMPLHR SNLKRDVAHL YRGVGSRYIM GSGESFMQLQ QRLLREKEAK IRKALDRLRK KRHLLRRQRT RREFPVISVV GYTNCGKTTL IKALTGDAAI QPRDQLFATL DVTAHAGTLP SRMTVLYVDT IGFLSQLPHG LIESFSATLE DVAHSDLILH VRDVSHPEAE LQKCSVLSTL RGLQLPAPLL DSMVEVHNKV DLVPGYSPTE PNVVPVSALR GHGLQELKAE LDAAVLKATG RQILTLRVRL AGAQLSWLYK EATVQEVDVI PEDGAADVRV IISNSAYGKF RKLFPG
Explore Putative GTP-binding protein 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets